Genentech, Inc. - Product Pipeline Review

Global Markets Direct’s, ‘Genentech, Inc. - Product Pipeline Review - 2016’, provides an overview of the Genentech, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genentech, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Genentech, Inc.

The report provides overview of Genentech, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Genentech, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Genentech, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Genentech, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Genentech, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Genentech, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Genentech, Inc. Snapshot 6

Genentech, Inc. Overview 6

Key Information ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Genentech, Inc. Snapshot 6

Genentech, Inc. Overview 6

Key Information 6

Key Facts 6

Genentech, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Genentech, Inc. - Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products - Monotherapy 13

Pipeline Products - Partnered Products 14

Pipeline Products - Out-Licensed Products 16

Genentech, Inc. - Pipeline Products Glance 18

Genentech, Inc. - Late Stage Pipeline Products 18

Genentech, Inc. - Clinical Stage Pipeline Products 19

Genentech, Inc. - Early Stage Pipeline Products 22

Genentech, Inc. - Drug Profiles 25

crenezumab 25

etrolizumab 27

lampalizumab 29

taselisib 31

duligotuzumab 33

ipatasertib 35

polatuzumab vedotin 37

quilizumab 39

RG-6046 40

RG-7745 41

BFKB-8488A 42

BTCT-4465A 43

DMUC-4064A 44

Drug for Inflammatory Diseases 45

DSTA-4637S 46

GDC-0134 47

GDC-0927 48

lifastuzumab vedotin 49

RG-6024 51

RG-6029 52

RG-7741 53

RG-7828 54

RG-7842 55

RG-7845 56

RG-7882 57

RG-7888 58

RG-7893 59

CS-3 60

G-007LK 61

G-244LM 62

GNE-293 63

GNE-317 64

GNE-3511 65

GNE-555 66

GNE-7915 67

GNE-892 68

MAb-30D8 69

Monoclonal Antibodies to Target CD98hc and BACE for Alzheimer's Disease 70

Monoclonal Antibody Conjugate for B-Cell Non Hodgkin's Lymphoma 71

Monoclonal Antibody Conjugates for Oncology 72

Monoclonal Antibody to Inhibit HtrA1 for Age Related Macular Degeneration 73

Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease and Neurodegenerative Disorders 74

MV-1 75

pictilisib 76

Small Molecule to Inhibit BACE1 for Alzheimer’s Disease 78

Small Molecule to Inhibit MAP4K4 for Cancer 79

Small Molecule to Inhibit TYK2 for Psoriasis and IBD 80

Small Molecules to Inhibit IRAK4 for Immunology and Oncology 81

Small Molecules to Inhibit JAK2 for Cancer 82

Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms 83

Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma 84

Small Molecules to Inhibit NAMPT for Cancer 85

Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders 86

Monoclonal Antibody Conjugated for Cancer 87

Small Molecule 2 for Undisclosed Indication 88

Small Molecule to Inhibit ITK for Asthma 89

Small Molecules 1 for Undisclosed Indication 90

Small Molecules for Central Nervous System Disorders 91

Small Molecules for Undisclosed Indication 92

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation 93

Small Molecules to Inhibit EGFR for Non-Small Cell Lung Cancer 94

Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases 95

Small Molecules to Inhibit Ubiquitin Specific Protease for Oncology 96

Genentech, Inc. - Pipeline Analysis 97

Genentech, Inc. - Pipeline Products by Target 97

Genentech, Inc. - Pipeline Products by Route of Administration 100

Genentech, Inc. - Pipeline Products by Molecule Type 101

Genentech, Inc. - Pipeline Products by Mechanism of Action 102

Genentech, Inc. - Recent Pipeline Updates 105

Genentech, Inc. - Dormant Projects 112

Genentech, Inc. - Discontinued Pipeline Products 113

Discontinued Pipeline Product Profiles 114

Genentech, Inc. - Company Statement 119

Genentech, Inc. - Locations and Subsidiaries 120

Head Office 120

Other Locations & Subsidiaries 120

Genentech, Inc. - Key Manufacturing Facilities 121

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Tables

List of Tables

Genentech, Inc., Key Information 11

Genentech, Inc., Key Facts 11

Genentech, Inc. - Pipeline by Indication, 2016 13

Genentech, Inc. - Pipeline ...

List of Tables

Genentech, Inc., Key Information 11

Genentech, Inc., Key Facts 11

Genentech, Inc. - Pipeline by Indication, 2016 13

Genentech, Inc. - Pipeline by Stage of Development, 2016 17

Genentech, Inc. - Monotherapy Products in Pipeline, 2016 18

Genentech, Inc. - Partnered Products in Pipeline, 2016 19

Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 20

Genentech, Inc. - Out-Licensed Products in Pipeline, 2016 21

Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 22

Genentech, Inc. - Phase III, 2016 23

Genentech, Inc. - Phase II, 2016 24

Genentech, Inc. - Phase I, 2016 25

Genentech, Inc. - Preclinical, 2016 27

Genentech, Inc. - Discovery, 2016 29

Genentech, Inc. - Pipeline by Target, 2016 102

Genentech, Inc. - Pipeline by Route of Administration, 2016 105

Genentech, Inc. - Pipeline by Molecule Type, 2016 106

Genentech, Inc. - Pipeline Products by Mechanism of Action, 2016 107

Genentech, Inc. - Recent Pipeline Updates, 2016 110

Genentech, Inc. - Dormant Developmental Projects,2016 117

Genentech, Inc. - Discontinued Pipeline Products, 2016 118

Genentech, Inc., Other Locations 125

Genentech, Inc., Key Manufacturing Facilities 126

List of Figures

List of Figures

Genentech, Inc. - Pipeline by Top 10 Indication, 2016 13

Genentech, Inc. - Pipeline by Stage of Development, 2016 17

Genentech, Inc. ...

List of Figures

Genentech, Inc. - Pipeline by Top 10 Indication, 2016 13

Genentech, Inc. - Pipeline by Stage of Development, 2016 17

Genentech, Inc. - Monotherapy Products in Pipeline, 2016 18

Genentech, Inc. - Partnered Products in Pipeline, 2016 19

Genentech, Inc. - Out-Licensed Products in Pipeline, 2016 21

Genentech, Inc. - Pipeline by Top 10 Target, 2016 102

Genentech, Inc. - Pipeline by Route of Administration, 2016 105

Genentech, Inc. - Pipeline by Molecule Type, 2016 106

Genentech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 107

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports